{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T23:14:18Z","timestamp":1784589258564,"version":"3.55.0"},"reference-count":50,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2019,11,29]],"date-time":"2019-11-29T00:00:00Z","timestamp":1574985600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"DOI":"10.3389\/fonc.2019.01301","type":"journal-article","created":{"date-parts":[[2019,11,29]],"date-time":"2019-11-29T11:15:05Z","timestamp":1575026105000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":20,"title":["The Dual Cell Cycle Kinase Inhibitor JNJ-7706621 Reverses Resistance to CD37-Targeted Radioimmunotherapy in Activated B Cell Like Diffuse Large B Cell Lymphoma Cell Lines"],"prefix":"10.3389","volume":"9","author":[{"given":"Gro Elise","family":"R\u00f8dland","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrine","family":"Melhus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roman","family":"Generalov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sania","family":"Gilani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Bertoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jostein","family":"Dahle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Randi G.","family":"Sylju\u00e5sen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Patzke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2019,11,29]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1002\/ajh.25460","article-title":"Diffuse large B-cell lymphoma: 2019 update on diagnosis, risk stratification, and treatment","volume":"94","author":"Liu","year":"2019","journal-title":"Am J Hematol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1093\/annonc\/mdy113","article-title":"Methodology of clinical trials evaluating the incorporation of new drugs in the first-line treatment of patients with diffuse large B-cell lymphoma (DLBCL): a critical review","volume":"29","author":"Iacoboni","year":"2018","journal-title":"Ann Oncol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1002\/hon.5_2629","article-title":"ROBUST: first report of phase III randomized study of lenalidomide\/R-CHOP (R2-CHOP) vs. placebo\/R-CHOP in previously untreated ABC-type diffuse large B-cell lymphoma","volume":"37","author":"Vitolo","year":"2019","journal-title":"Hematol Oncol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1200\/JCO.18.02403","article-title":"Randomized phase III trial of ibrutinib and rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in non-germinal center B-cell diffuse large B-cell lymphoma","volume":"37","author":"Younes","year":"2019","journal-title":"J Clin Oncol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1056\/NEJMoa1801445","article-title":"Genetics and pathogenesis of diffuse large B-cell lymphoma","volume":"378","author":"Schmitz","year":"2018","journal-title":"N Engl J Med"},{"key":"B6","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1038\/s41591-018-0016-8","article-title":"Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes","volume":"24","author":"Chapuy","year":"2018","journal-title":"Nat Med"},{"key":"B7","doi-asserted-by":"publisher","first-page":"4622","DOI":"10.1002\/cncr.31646","article-title":"Double hit and double expressors in lymphoma: definition and treatment","volume":"124","author":"Riedell","year":"2018","journal-title":"Cancer"},{"key":"B8","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1200\/JCO.18.01314","article-title":"Molecular high-grade B-cell lymphoma: defining a poor-risk group that requires different approaches to therapy","volume":"37","author":"Sha","year":"2019","journal-title":"J Clin Oncol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1586\/14737140.6.3.445","article-title":"Review of clinical radioimmunotherapy","volume":"6","author":"Pohlman","year":"2006","journal-title":"Expert Rev Anticancer Ther"},{"key":"B10","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1158\/0008-5472.CAN-16-2523","article-title":"Whither radioimmunotherapy: to be or not to be?","volume":"77","author":"Green","year":"2017","journal-title":"Cancer Res."},{"key":"B11","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1111\/bjh.12906","article-title":"R-CHOP with iodine-131 tositumomab consolidation for advanced stage diffuse large B-cell lymphoma (DLBCL): SWOG S0433","volume":"166","author":"Friedberg","year":"2014","journal-title":"Br J Haematol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"7597","DOI":"10.18632\/oncotarget.6531","article-title":"90 Y-ibritumomab tiuxetan: a nearly forgotten opportunityr","volume":"7","author":"Mondello","year":"2016","journal-title":"Oncotarget"},{"key":"B13","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1177\/107327481201900304","article-title":"Radioimmunotherapy for B-cell non-hodgkin lymphomas","volume":"19","author":"Tomblyn","year":"2012","journal-title":"Cancer Control"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.1200\/JCO.2012.45.9453","article-title":"Phase III randomized study of rituximab\/carmustine, etoposide, cytarabine, and melphalan (BEAM) compared with iodine-131 tositumomab\/BEAM with autologous hematopoietic cell transplantation for relapsed diffuse large B-cell lymphoma: results from the BMT CTN 0401 trial","volume":"31","author":"Vose","year":"2013","journal-title":"J Clin Oncol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"3022","DOI":"10.1182\/blood-2016-11-748137","article-title":"Staining the target: CD37 expression in lymphomas","volume":"128","author":"Bertoni","year":"2016","journal-title":"Blood"},{"key":"B16","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1111\/bjh.15232","article-title":"A tale of two antibodies: obinutuzumab versus rituximab","volume":"182","author":"Freeman","year":"2018","journal-title":"Br J Haematol."},{"key":"B17","unstructured":"Evaluating antigen targeting and anti-tumor activity of a new anti-CD37 radioimmunoconjugate against non-Hodgkins lymphoma8595\n            DahleJ\n            Repetto-LlamazaresAH\n            MollattCS\n            MelhusKB\n            BrulandOS\n            KolstadA\n          Anticancer Res332013"},{"key":"B18","doi-asserted-by":"publisher","first-page":"e103070","DOI":"10.1371\/journal.pone.0103070","article-title":"177Lu-DOTA-HH1, a novel anti-CD37 radio-immunoconjugate: a study of toxicity in nude mice","volume":"9","author":"Repetto-Llamazares","year":"2014","journal-title":"PLoS ONE"},{"key":"B19","doi-asserted-by":"publisher","first-page":"e0128816","DOI":"10.1371\/journal.pone.0128816","article-title":"Targeted cancer therapy with a novel anti-CD37 beta-particle emitting radioimmunoconjugate for treatment of non-hodgkin lymphoma","volume":"10","author":"Repetto-Llamazares","year":"2015","journal-title":"PLoS ONE"},{"key":"B20","doi-asserted-by":"publisher","first-page":"2879","DOI":"10.1182\/blood-2018-99-110555","article-title":"LYMRIT 37-01: a phase I\/II study of 177Lu-lilotomab satetraxetan (Betalutin\u00ae) antibody-radionuclide-conjugate (ARC) for the treatment of relapsed non-hodgkins lymphoma (NHL) \u2014 Analysis with 6-month follow-up","volume":"132","author":"Kolstad","year":"2018","journal-title":"Blood"},{"key":"B21","doi-asserted-by":"publisher","first-page":"5167","DOI":"10.1158\/1078-0432.CCR-18-2718","article-title":"The ETS inhibitors YK-4-279 and TK-216 are novel anti-lymphoma agents","volume":"25","author":"Spriano","year":"2019","journal-title":"Clin Cancer Res."},{"key":"B22","doi-asserted-by":"publisher","first-page":"4275","DOI":"10.1158\/1538-7445.AM2018-4275","article-title":"Abstract 4275: analysis of gene and protein expression in lymphoma cell lines using multiple platforms","volume":"78","author":"Cascione","year":"2018","journal-title":"Cancer Res."},{"key":"B23","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1158\/1078-0432.CCR-17-1041","article-title":"PQR309 is a novel dual PI3K\/mTOR inhibitor with preclinical antitumor activity in lymphomas as a single agent and in combination therapy","volume":"24","author":"Tarantelli","year":"2018","journal-title":"Clin Cancer Res"},{"key":"B24","doi-asserted-by":"publisher","first-page":"14639","DOI":"10.1073\/pnas.1008522107","article-title":"Histone deacetylase inhibitor induces DNA damage, which normal but not transformed cells can repair","volume":"107","author":"Lee","year":"2010","journal-title":"Proc Natl Acad Sci USA."},{"key":"B25","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1080\/10428190701769657","article-title":"Influence of DNA damage and repair upon the risk of treatment related leukemia","volume":"49","author":"Guillem","year":"2008","journal-title":"Leuk Lymphoma"},{"key":"B26","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1042\/BCJ20160583","article-title":"Topoisomerases as anticancer targets","volume":"475","author":"Delgado","year":"2018","journal-title":"Biochem J."},{"key":"B27","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1083\/jcb.200812045","article-title":"The decision to enter mitosis: feedback and redundancy in the mitotic entry network","volume":"185","author":"Lindqvist","year":"2009","journal-title":"J Cell Biol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/nrc.2016.138","article-title":"Cell cycle proteins as promising targets in cancer therapy","volume":"17","author":"Otto","year":"2017","journal-title":"Nat Rev Cancer"},{"key":"B29","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1083\/jcb.201808077","article-title":"Anti-mitotic therapies in cancer","volume":"218","author":"Tischer","year":"2019","journal-title":"J Cell Biol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"9038","DOI":"10.1158\/0008-5472.CAN-05-0882","article-title":"The in vitro and in vivo effects of JNJ-7706621: a dual inhibitor of cyclin-dependent kinases and aurora kinases","volume":"65","author":"Emanuel","year":"2005","journal-title":"Cancer Res"},{"key":"B31","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1182\/blood-2018-99-111399","article-title":"Subclonal mutations of TP53 are common in untreated follicular lymphoma and mutation status is predictive of PFS when CHOP is combined with 131-iodine tositumomab but not with rituximab: an analysis of SWOG S0016","volume":"132","author":"Burack","year":"2018","journal-title":"Blood"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.1038\/leu.2015.99","article-title":"Synergistic induction of apoptosis in high-risk DLBCL by BCL2 inhibition with ABT-199 combined with pharmacologic loss of MCL1","volume":"29","author":"Li","year":"2015","journal-title":"Leukemia"},{"key":"B33","doi-asserted-by":"publisher","first-page":"3885","DOI":"10.1158\/0008-5472.CAN-17-0082","article-title":"Venetoclax synergizes with radiotherapy for treatment of B-cell lymphomas","volume":"77","author":"O'Steen","year":"2017","journal-title":"Cancer Res."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1634\/theoncologist.12-10-1247","article-title":"FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma","volume":"12","author":"Mann","year":"2007","journal-title":"Oncologist."},{"key":"B35","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1200\/JCO.2012.46.8793","article-title":"Phase II study of alisertib, a selective Aurora A kinase inhibitor, in relapsed and refractory aggressive B- and T-cell non-Hodgkin lymphomas","volume":"32","author":"Friedberg","year":"2014","journal-title":"J Clin Oncol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"6150","DOI":"10.1158\/1078-0432.CCR-18-0286","article-title":"Phase I study of the investigational aurora A kinase inhibitor alisertib plus rituximab or rituximab\/vincristine in relapsed\/refractory aggressive B-cell lymphoma","volume":"24","author":"Kelly","year":"2018","journal-title":"Clin Cancer Res."},{"key":"B37","doi-asserted-by":"publisher","first-page":"3420","DOI":"10.1158\/1078-0432.CCR-10-2946","article-title":"Phase I study of GSK461364, a specific and competitive Polo-like kinase 1 inhibitor, in patients with advanced solid malignancies","volume":"17","author":"Olmos","year":"2011","journal-title":"Clin Cancer Res"},{"key":"B38","doi-asserted-by":"publisher","first-page":"3885","DOI":"10.1021\/acs.molpharmaceut.5b00312","article-title":"Human ATP-binding cassette transporter ABCB1 confers resistance to volasertib (BI 6727), a selective inhibitor of polo-like kinase 1","volume":"12","author":"Wu","year":"2015","journal-title":"Mol Pharm"},{"key":"B39","doi-asserted-by":"publisher","first-page":"3727","DOI":"10.1021\/mp500492r","article-title":"Overexpression of human ABCB1 in cancer cells leads to reduced activity of GSK461364, a specific inhibitor of polo-like kinase 1","volume":"11","author":"Wu","year":"2014","journal-title":"Mol Pharm"},{"key":"B40","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1016\/j.bcp.2013.08.004","article-title":"Human ABCB1 (P-glycoprotein) and ABCG2 mediate resistance to BI 2536, a potent and selective inhibitor of Polo-like kinase 1","volume":"86","author":"Wu","year":"2013","journal-title":"Biochem Pharmacol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/j.cell.2017.09.027","article-title":"Genetic and functional drivers of diffuse large B cell lymphoma","volume":"171","author":"Reddy","year":"2017","journal-title":"Cell"},{"key":"B42","doi-asserted-by":"publisher","first-page":"e95184","DOI":"10.1371\/journal.pone.0095184","article-title":"Alisertib added to rituximab and vincristine is synthetic lethal and potentially curative in mice with aggressive DLBCL co-overexpressing MYC and BCL2","volume":"9","author":"Mahadevan","year":"2014","journal-title":"PLoS ONE"},{"key":"B43","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1158\/1535-7163.MCT-17-0089","article-title":"Disruption of aneuploidy and senescence induced by aurora inhibition promotes intrinsic apoptosis in double hit or double expressor diffuse large B-cell lymphomas","volume":"16","author":"Islam","year":"2017","journal-title":"Mol Cancer Ther"},{"key":"B44","doi-asserted-by":"publisher","first-page":"35875","DOI":"10.18632\/oncotarget.26251","article-title":"Drug-induced aneuploidy and polyploidy is a mechanism of disease relapse in MYC\/BCL2-addicted diffuse large B-cell lymphoma","volume":"9","author":"Islam","year":"2018","journal-title":"Oncotarget"},{"key":"B45","doi-asserted-by":"publisher","first-page":"625","DOI":"10.2174\/156800912801784839","article-title":"Growth suppression and mitotic defect induced by JNJ-7706621, an inhibitor of cyclin-dependent kinases and aurora kinases","volume":"12","author":"Matsuhashi","year":"2012","journal-title":"Curr Cancer Drug Targets"},{"key":"B46","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.ijpharm.2010.03.018","article-title":"Active and passive tumor targeting of a novel poorly soluble cyclin dependent kinase inhibitor, JNJ-7706621","volume":"392","author":"Danhier","year":"2010","journal-title":"Int J Pharm"},{"key":"B47","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1158\/2159-8290.CD-14-0403","article-title":"DNA-damage response during mitosis induces whole-chromosome missegregation","volume":"4","author":"Bakhoum","year":"2014","journal-title":"Cancer Discov."},{"key":"B48","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.trecan.2017.02.001","article-title":"Mitotic DNA damage response: at the crossroads of structural and numerical cancer chromosome instabilities","volume":"3","author":"Bakhoum","year":"2017","journal-title":"Trends Cancer."},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1002\/0471250953.bi0703s21","article-title":"Analysis of gene-expression data using J-Express","author":"Stavrum","year":"2008","journal-title":"Curr Protoc Bioinformatics"},{"key":"B50","volume-title":"CompuSyn for Drug Combinations: PC Software and Users Guide: A Computer Program for Quantitation of Synergism and Antagonism in Drug Combinations, and the Determination of IC50 and ED50 and LD50 Values","author":"Chou","year":"2005"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fonc.2019.01301\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,29]],"date-time":"2019-11-29T11:15:09Z","timestamp":1575026109000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fonc.2019.01301\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,29]]},"references-count":50,"alternative-id":["10.3389\/fonc.2019.01301"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2019.01301","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,29]]},"article-number":"1301"}}